Answers are grounded in this paper and cite their sources.
Eleven months after commencing 0.25% topical finasteride lotion daily for Norwood-Hamilton stage V male pattern hair loss (MPHL), a 76-year-old gentleman noticed worsening bilateral breast enlargement and breast tenderness. His symptoms were consistent with grade three gynaecomastia. The topical finasteride was ceased. The breast tenderness had resolved within 1 month, though the gynaecomastia persisted. Several years prior he had developed gynaecomastia secondary to oral finasteride with partial resolution following finasteride cessation. No other side effects were reported. Other than age, there were no other predisposing factors for gynaecomastia. The patient was of a normal BMI, had no history of alcohol abuse, liver failure, hyperthyroidism, or renal failure, and was not using any other medications with gynaecomastia as a known side effect. Gynaecomastia is the benign proliferation of glandular breast tissue in males.1 It occurs in 35% of men, with prevalence increasing with age.1 Oestrogens stimulate breast development whereas testosterone is a potent inhibitor. An excess of oestrogens, or decrease in androgens or inhibition of their effects can cause gynaecomastia.1 Gynaecomastia in elderly men occurs as a result of decreasing testosterone levels and testicular involution.1 Gynaecomastia is usually asymptomatic, though can be painful or tender2 as was seen in this case. Finasteride is a 5-alpha reductase inhibitor that reduces the conversion of testosterone to dihydrotestosterone (DHT).3 A single dose of 1 mg oral finasteride causes a far greater reduction in circulating DHT levels than a single application of 0.25% topical solution to the scalp.4 However, after several doses, DHT levels are similar in patients using oral or topical finasteride.4 When applied to the scalp for MPHL, the most commonly reported adverse events are localized erythema and pruritus.4 There are several reports of gynaecomastia following oral finasteride.3, 5 The majority of cases are unilateral and occur in males in their twenties.3 To the best of our knowledge, this is the first report of gynaecomastia secondary to topical finasteride. This side effect appears rare with the topical formulation and was not seen in a phase three clinical trial.6 Finasteride-induced gynaecomastia is attributed to an increase in the conversion of testosterone to oestradiol by peripheral aromatases, thereby increasing circulating oestrogen levels. Finasteride-induced gynaecomastia often resolves spontaneously after ceasing finasteride, though if present for greater than a year, the resolution is less likely due to fibrosis of the ductal tissue.3 None. Rodney Sinclair is an Editorial Board member of the Australasian Journal of Dermatology and a co-author of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication. The patients/patients' legal guardian in this manuscript have given written informed consent to the publication of their case details. Data sharing is not applicable to this article as no new data were created or analyzed in this study.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: